This article reviews the usefulness of various types of blood-derived
biomarkers that are currently being studied to predict the progression of
Chagas disease in patients with the indeterminate form, to assess the efficacy of
antiparasitic drugs and to identify early cardiac and gastrointestinal damage. The authors used a search strategy based on MEDLINE, Cochrane Library Register for systematic review, EmBase, Global Health and LILACS databases. Out of 1716 screened articles, only 166 articles were eligible for final inclusion. The authors classified the
biomarkers according to their biochemical structure and primary
biological activity in four groups: i) markers of
inflammation and cellular injury, ii) metabolic biomakers, iii) prothrombotic
biomarkers and iv) markers derived from specific
antigens of the parasite. Several potential
biomarkers might have clinical potential for the detection of early cardiopathy. Such capacity is imperative in order to detect high-risk patients who require intensive monitoring and earlier
therapy. Prospective studies with longer follow-ups are needed for the appraisal of
biomarkers assessing clinical or microbiological cure after
therapy. At the same time, studies evaluating more than one
biomarker are useful to compare the efficacy among them given the lack of a recognized gold standard.